DE69733035T2 - Chimäres retrovirus/adenovirus system - Google Patents

Chimäres retrovirus/adenovirus system Download PDF

Info

Publication number
DE69733035T2
DE69733035T2 DE69733035T DE69733035T DE69733035T2 DE 69733035 T2 DE69733035 T2 DE 69733035T2 DE 69733035 T DE69733035 T DE 69733035T DE 69733035 T DE69733035 T DE 69733035T DE 69733035 T2 DE69733035 T2 DE 69733035T2
Authority
DE
Germany
Prior art keywords
vector
adenovirus
retroviral
cells
retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69733035T
Other languages
German (de)
English (en)
Other versions
DE69733035D1 (en
Inventor
T. David CURIEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of DE69733035D1 publication Critical patent/DE69733035D1/de
Publication of DE69733035T2 publication Critical patent/DE69733035T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69733035T 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system Expired - Lifetime DE69733035T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3132396P 1996-11-19 1996-11-19
US31323P 1996-11-19
US3708197P 1997-02-04 1997-02-04
US37081P 1997-02-04
PCT/US1997/021169 WO1998022143A1 (en) 1996-11-19 1997-11-19 Chimeric retrovirus/adenovirus system

Publications (2)

Publication Number Publication Date
DE69733035D1 DE69733035D1 (en) 2005-05-19
DE69733035T2 true DE69733035T2 (de) 2005-11-24

Family

ID=26707084

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69733035T Expired - Lifetime DE69733035T2 (de) 1996-11-19 1997-11-19 Chimäres retrovirus/adenovirus system

Country Status (8)

Country Link
US (1) US6333030B1 (enExample)
EP (1) EP0956052B1 (enExample)
JP (1) JP4214239B2 (enExample)
AT (1) ATE292983T1 (enExample)
AU (1) AU728610B2 (enExample)
CA (1) CA2272121A1 (enExample)
DE (1) DE69733035T2 (enExample)
WO (1) WO1998022143A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010006629A1 (en) * 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
AU687117B2 (en) * 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US20060275261A1 (en) * 1993-10-25 2006-12-07 Canji, Inc. Adenoviral vectors having a protein IX deletion
JP2001518804A (ja) * 1997-03-21 2001-10-16 エンゾー セラピューティクス インコーポレイテッド ベクターおよびウイルスベクター、およびこれらを増殖するためのパッケージング細胞株
US8703480B1 (en) 1997-03-21 2014-04-22 Enzo Therapeutics, Inc. Biological function effecting viral vectors and chimeric cells useful as packaging cell lines and target cells
AU6962698A (en) 1997-04-11 1998-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Transgenomic viruses and the use thereof
WO1999044423A1 (en) * 1998-03-03 1999-09-10 The Uab Research Foundation Amplification of gene transfer and gene therapy by controlled replication
US20060183228A1 (en) * 1998-03-24 2006-08-17 Enzo Therapeutics, Inc. Viral vectors with surface or envelope components
FR2778670B1 (fr) 1998-05-18 2002-12-13 Rhone Poulenc Rorer Sa Methodes et compositions pour la production de particules virales
AU6149099A (en) * 1998-09-22 2000-04-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Replication deficient retroviral vector system and methods of using
US7052904B2 (en) 2000-01-31 2006-05-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hybrid adeno-retroviral vector for the transfection of cells
EP1287153B1 (en) 2000-05-31 2009-09-30 Human Gene Therapy Research Institute Methods and compositions for efficient gene transfer using transcomplementary vectors
US7226779B2 (en) 2001-01-30 2007-06-05 The United States Of America As Represented By The Department Of Health And Human Services Hybrid adenoviral vector
US7271150B2 (en) 2001-05-14 2007-09-18 United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified growth hormone
EP1442125A4 (en) * 2001-10-04 2004-12-08 Carlos Estuard Aguilar-Cordova CHIMERAL VIRUS VECTORS FOR GENE THERAPY
US20070037284A1 (en) * 2003-06-04 2007-02-15 Enzo Therapeutics, Inc. Vectors for expressing exogenous gene or exogenous nucleic acid sequences
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
WO2021108500A1 (en) 2019-11-26 2021-06-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors targeting mutations in rna splicing factors
US20230348557A1 (en) 2020-02-06 2023-11-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education T cell receptors Targeting Defective DNA Repair Proteins
US10822379B1 (en) 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
EP0956052A1 (en) 1999-11-17
AU5447598A (en) 1998-06-10
US6333030B1 (en) 2001-12-25
JP2001509009A (ja) 2001-07-10
JP4214239B2 (ja) 2009-01-28
WO1998022143A1 (en) 1998-05-28
EP0956052B1 (en) 2005-04-13
ATE292983T1 (de) 2005-04-15
CA2272121A1 (en) 1998-05-28
AU728610B2 (en) 2001-01-11
DE69733035D1 (en) 2005-05-19
EP0956052A4 (en) 2001-05-02

Similar Documents

Publication Publication Date Title
DE69733035T2 (de) Chimäres retrovirus/adenovirus system
DE69830798T2 (de) Retrovirale vektoren, die funktionelle spleiss-donor- und spleiss-akzeptor-stellen enthalten
DE69636581T2 (de) Retrovirale Vektoren
DE69834936T2 (de) Vektor zur gewebespezifischen replikation und expression
DE69518910T3 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DE69131908T2 (de) Viruspartikel mit veraendertem wirtspektrum
DE69534166T2 (de) Rekombinanter adenovirus und methoden zu dessen verwendung
DE69434860T2 (de) Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion
DE69633565T2 (de) Verpackungssysteme für humane rekombinante adenoviren, zur vewendung in der ge ntherapie
DE69420033T2 (de) Gibbon leukemia virus retrovirale vektoren
DE60018920T2 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
DE19856463B4 (de) Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
EP2430167B1 (de) Aslv-vektorsystem
DE60038555T2 (de) Verpackungszelle
EP0781343B1 (de) Retrovirale vektorhybride und deren verwendung zum gentransfer
DE19752855C2 (de) Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
EP0975783B1 (de) Retrovirale vektoren, verfahren zu ihrer herstellung und ihre verwendung zur genübertragung in cd4-positive zellen
DE69716581T2 (de) Retroviraler vektor und dessen verwendung in gentherapie
DE69612660T2 (de) Pseudotypisierte retrovirale vektoren
EP0933429B1 (de) Chimäres Poxvirus, das ein retrovirales Vektorgenom enthält
DE19807265C2 (de) Adenoviraler Transfervektor für den Gentransport einer DNA-Sequenz
DE69621949T2 (de) Toxisches protein exprimierende viren und produktionszellinien
DE10045016B4 (de) Retrovirale Vektoren mit Fremdsequenzinsertion zwischen retroviraler Primerbindungsstelle und retroviralem Spleißdonor
EP1216299A2 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
DE69829174T2 (de) Exprimierung eines modifiziertem "foamy virus envelope protein" (hüllenprotein)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: HOEFER & PARTNER, 81543 MUENCHEN